The conventional paradigm that a viable treatment for cancer will come from a toxic synthesized drug and not an alternative non-toxic remedy is reflected in how our research dollars are spent. For example, there are thousands of cancer clinical trials. Many of these are funded or partially funded by our tax dollars through the National Cancer Institute (NCI). Others are funded wholly by pharmaceutical companies, foundations, and medical centers. Cancer Monthly recently performed a cursory analysis to determine which and how many clinical trials are focused on alternative or complementary therapies. The results were disappointing, but not surprising.